Research of Tyrosinemia, Type I has been linked to Tyrosinemias, Liver Carcinoma, Metabolic Diseases, Carcinoma, Liver Diseases. The study of Tyrosinemia, Type I has been mentioned in research publications which can be found using our bioinformatics tool below. Researched pathways related to Tyrosinemia, Type I include Excretion, Pathogenesis, Urea Cycle, Fatty Acid Oxidation, Regeneration. These pathways complement our catalog of research reagents for the study of Tyrosinemia, Type I including antibodies and ELISA kits against FAH, FANCA, FUMARYLACETOACETATE HYDROLASE, HPD, AFP.
Tyrosinemia, Type I Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Tyrosinemia, Type I below!
For more information on how to use Laverne, please read the How to Guide.
We have 1031 products for the study of Tyrosinemia, Type I that can be applied to Western Blot, Chromatin Immunoprecipitation, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Tyrosinemia, Type I is also known as Deficiency Of Fumarylacetoacetase, Fumarylacetoacetase Deficiency, Hepatorenal Tyrosinemia, Hereditary Tyrosinaemia Type I, Hereditary Tyrosinemia Type I.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.